BR112015004548A2 - inibidores de serina/treonina para tratamento de doenças hiperproliferativas - Google Patents
inibidores de serina/treonina para tratamento de doenças hiperproliferativasInfo
- Publication number
- BR112015004548A2 BR112015004548A2 BR112015004548A BR112015004548A BR112015004548A2 BR 112015004548 A2 BR112015004548 A2 BR 112015004548A2 BR 112015004548 A BR112015004548 A BR 112015004548A BR 112015004548 A BR112015004548 A BR 112015004548A BR 112015004548 A2 BR112015004548 A2 BR 112015004548A2
- Authority
- BR
- Brazil
- Prior art keywords
- serine
- treatment
- hyperproliferative diseases
- threonine
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261693671P | 2012-08-27 | 2012-08-27 | |
| PCT/US2013/056876 WO2014036015A1 (en) | 2012-08-27 | 2013-08-27 | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015004548A2 true BR112015004548A2 (pt) | 2017-08-08 |
Family
ID=49118823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015004548A BR112015004548A2 (pt) | 2012-08-27 | 2013-08-27 | inibidores de serina/treonina para tratamento de doenças hiperproliferativas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9388171B2 (pt) |
| EP (1) | EP2888247B1 (pt) |
| JP (1) | JP6378182B2 (pt) |
| KR (1) | KR20150047597A (pt) |
| CN (1) | CN105143200B (pt) |
| AR (1) | AR092253A1 (pt) |
| BR (1) | BR112015004548A2 (pt) |
| CA (1) | CA2882750A1 (pt) |
| HK (1) | HK1210174A1 (pt) |
| MX (1) | MX369989B (pt) |
| RU (1) | RU2644947C2 (pt) |
| TW (1) | TW201408658A (pt) |
| WO (1) | WO2014036015A1 (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2681215B1 (en) | 2011-02-28 | 2015-04-22 | Array Biopharma, Inc. | Serine/threonine kinase inhibitors |
| ES2552989T3 (es) | 2011-08-04 | 2015-12-03 | Array Biopharma, Inc. | Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina |
| AR090220A1 (es) | 2012-03-01 | 2014-10-29 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
| US9522889B2 (en) | 2012-07-27 | 2016-12-20 | Biogen Ma Inc. | ATX modulating agents |
| CN104755478B (zh) | 2012-10-16 | 2017-10-10 | 霍夫曼-拉罗奇有限公司 | 丝氨酸/苏氨酸激酶抑制剂 |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| CR20160309A (es) | 2013-12-06 | 2016-08-25 | Genentech Inc | Inhibidores de serina/treonina cinasa |
| BR112016015235A2 (pt) | 2013-12-30 | 2017-08-08 | Genentech Inc | Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento |
| MX2016008624A (es) | 2013-12-30 | 2017-01-06 | Genentech Inc | Inhibidores de serina/treonina cinasa. |
| US9879029B2 (en) * | 2014-12-22 | 2018-01-30 | Eli Lilly And Company | ERK inhibitors |
| JP2019518426A (ja) | 2016-04-15 | 2019-07-04 | ジェネンテック， インコーポレイテッド | がんの診断及び治療方法 |
| CN106749117B (zh) * | 2016-11-29 | 2018-10-09 | 北京怡力生物科技有限公司 | 一种3-氨基甲基四氢呋喃的制备方法 |
| JP7129420B6 (ja) | 2017-03-30 | 2024-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｐｋ１阻害剤としてのイソキノリン |
| EP3640242B1 (en) * | 2017-06-16 | 2023-04-19 | Hitgen Ltd. | Rock-inhibiting compound and uses thereof |
| CA3073073A1 (en) | 2017-09-08 | 2019-03-14 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for cancer |
| WO2019158579A1 (en) | 2018-02-13 | 2019-08-22 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| CN108558869B (zh) * | 2018-05-10 | 2019-04-09 | 西安培华学院 | 用于治疗肝癌的化合物及其制剂 |
| WO2020023560A1 (en) * | 2018-07-24 | 2020-01-30 | F. Hoffmann-La Roche Ag | Isoquinoline compounds and uses thereof |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| JP7284830B2 (ja) | 2019-04-02 | 2023-05-31 | アレイ バイオファーマ インコーポレイテッド | タンパク質チロシンホスファターゼ阻害剤 |
| EP4211119A1 (en) * | 2020-09-02 | 2023-07-19 | Merck Sharp & Dohme LLC | 2-aminoquinazolines as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0672035A1 (en) | 1993-10-01 | 1995-09-20 | Novartis AG | Pyrimidineamine derivatives and processes for the preparation thereof |
| JP3588116B2 (ja) | 1993-10-01 | 2004-11-10 | ノバルティス アクチェンゲゼルシャフト | 薬理活性のピリミジンアミン誘導体およびその製造方法 |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| CZ9902016A3 (cs) | 1996-12-05 | 1999-11-17 | Amgen Inc. | Substituované pyrimidinonové a pyridonové sloučeniny a způsoby jejich použití |
| GB9812683D0 (en) * | 1998-06-12 | 1998-08-12 | Smithkline Beecham Plc | Novel compounds |
| US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
| HUP0300029A2 (en) | 2000-02-25 | 2003-05-28 | Hoffmann La Roche | Adenosine receptor modulators, pharmaceutical compositions containing them and their use |
| US7189717B2 (en) | 2000-04-26 | 2007-03-13 | Eisai Co., Ltd. | Medicinal compositions promoting bowel movement |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| CA2485166A1 (en) | 2002-05-21 | 2003-12-04 | Amgen Inc. | Substituted pyrimidinone and pyridinone compounds |
| WO2004007468A1 (en) | 2002-07-15 | 2004-01-22 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| TW200533357A (en) | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| US7560464B2 (en) | 2004-04-13 | 2009-07-14 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US20080187575A1 (en) | 2004-08-27 | 2008-08-07 | Bert Klebl | Pyrimidine Derivatives |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| AR053712A1 (es) | 2005-04-18 | 2007-05-16 | Neurogen Corp | Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide) |
| US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| DE602007009932D1 (de) | 2006-02-16 | 2010-12-02 | Schering Corp | Pyrrolidin-derivate als erk-hemmer |
| EP2024342A2 (en) * | 2006-05-01 | 2009-02-18 | Pfizer Products Incorporated | Substituted 2-amino-fused heterocyclic compounds |
| DE102006035202A1 (de) | 2006-07-29 | 2008-01-31 | Lanxess Deutschland Gmbh | Konservierungsmittel auf Basis von Carbonsäureanhydriden |
| TWI389899B (zh) * | 2006-08-08 | 2013-03-21 | Msd Oss Bv | 具口服活性之凝血酶抑制劑 |
| EP2057141B1 (en) | 2006-08-23 | 2011-10-26 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| MX2009006536A (es) | 2006-12-22 | 2009-06-26 | Novartis Ag | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. |
| PT2200436E (pt) | 2007-09-04 | 2015-04-29 | Scripps Research Inst | Pirimidinilaminas substituídas como inibidoras da proteína quinase |
| MX2010005033A (es) | 2007-11-06 | 2010-05-27 | Du Pont | Aminas heterociclicas fungicidas. |
| US20090246198A1 (en) | 2008-03-31 | 2009-10-01 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
| PE20110136A1 (es) | 2008-06-27 | 2011-03-17 | Novartis Ag | Compuestos organicos |
| ES2711249T3 (es) | 2008-06-27 | 2019-04-30 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
| PL2370413T3 (pl) | 2008-12-08 | 2016-01-29 | Arena Pharm Inc | Modulatory receptora prostacykliny (PGI2) użyteczne w leczeniu zaburzeń z nimi związanych |
| EP2681215B1 (en) | 2011-02-28 | 2015-04-22 | Array Biopharma, Inc. | Serine/threonine kinase inhibitors |
| ES2552989T3 (es) * | 2011-08-04 | 2015-12-03 | Array Biopharma, Inc. | Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina |
| AR090220A1 (es) | 2012-03-01 | 2014-10-29 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
-
2013
- 2013-08-27 JP JP2015529957A patent/JP6378182B2/ja active Active
- 2013-08-27 WO PCT/US2013/056876 patent/WO2014036015A1/en active Application Filing
- 2013-08-27 MX MX2015002508A patent/MX369989B/es active IP Right Grant
- 2013-08-27 EP EP13759395.0A patent/EP2888247B1/en active Active
- 2013-08-27 RU RU2015110985A patent/RU2644947C2/ru not_active IP Right Cessation
- 2013-08-27 TW TW102130680A patent/TW201408658A/zh unknown
- 2013-08-27 KR KR1020157007729A patent/KR20150047597A/ko not_active Application Discontinuation
- 2013-08-27 AR ARP130103040A patent/AR092253A1/es unknown
- 2013-08-27 CA CA2882750A patent/CA2882750A1/en not_active Abandoned
- 2013-08-27 BR BR112015004548A patent/BR112015004548A2/pt not_active IP Right Cessation
- 2013-08-27 CN CN201380051518.1A patent/CN105143200B/zh active Active
- 2013-08-27 US US14/011,501 patent/US9388171B2/en active Active
-
2015
- 2015-11-10 HK HK15111084.7A patent/HK1210174A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014036015A1 (en) | 2014-03-06 |
| MX2015002508A (es) | 2015-10-12 |
| CN105143200B (zh) | 2018-10-16 |
| EP2888247B1 (en) | 2020-03-25 |
| MX369989B (es) | 2019-11-27 |
| CA2882750A1 (en) | 2014-03-06 |
| EP2888247A1 (en) | 2015-07-01 |
| RU2015110985A (ru) | 2016-10-20 |
| US9388171B2 (en) | 2016-07-12 |
| RU2644947C2 (ru) | 2018-02-15 |
| HK1210174A1 (en) | 2016-04-15 |
| US20140066453A1 (en) | 2014-03-06 |
| TW201408658A (zh) | 2014-03-01 |
| JP6378182B2 (ja) | 2018-08-22 |
| KR20150047597A (ko) | 2015-05-04 |
| CN105143200A (zh) | 2015-12-09 |
| JP2015526519A (ja) | 2015-09-10 |
| AR092253A1 (es) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015004548A2 (pt) | inibidores de serina/treonina para tratamento de doenças hiperproliferativas | |
| CY2019033I2 (el) | Μακροκυκλικα παραγωγα για την αγωγη υπερπλαστικων παθησεων | |
| HK1212972A1 (zh) | 作爲 -蛋白抑制劑用於治療過度增殖性疾病的吡咯並-和吡唑並-三唑並二氮雜卓 | |
| IL243976A0 (en) | kdm1a inhibitors for disease treatment | |
| CO7061086A2 (es) | Combinaciones de compuestos activos | |
| CO6791604A2 (es) | Compuesto para liberación controlada de agentes de tratamiento de pozos | |
| CO6940432A2 (es) | Compuestos de 1-arilcarbonilo-4-oxi-piperidina útiles para el tratamiento de enfermedades neurodegenerativas | |
| BR112014000033A2 (pt) | compostos para o tratamento de dependência química | |
| AP4029A (en) | Inhibitors of beta-secretase | |
| DK2872497T4 (da) | Chromanyl-derivater til behandling af mitokondriel sygdom | |
| EP2968321A4 (en) | COMPOUNDS FOR THE TREATMENT OF FIBROSIS DISEASES | |
| EP2994460A4 (en) | Compounds for treatment of angiogenesis-mediated diseases | |
| BR112013030370A2 (pt) | compostos de quinona para tratamento de doenças mediadas por ape1 | |
| IL236963A0 (en) | beta-secretase inhibitors | |
| HK1216504A1 (zh) | 疾病的治療方法 | |
| IL238592B (en) | Compounds for the treatment of liver diseases | |
| ITRM20120530A1 (it) | Compounds for use in the treatment of parasitic diseases | |
| CR20130603A (es) | Compuestos novedosos como inhibidores de diacilglicerol | |
| EP2897607A4 (en) | BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
| DK2825636T3 (da) | Behandling af sædceller | |
| IL234796B (en) | Compounds for the treatment of diseases related to ischemia-reperfusion | |
| ITRM20120473A1 (it) | Use of glycerophosphoinositols for the treatment of septic shock | |
| FR2997080B1 (fr) | Inhibiteurs de neprilysine | |
| ES1087856Y (es) | Aposento para tratamiento terapeutico de animales | |
| BR112014005858A2 (pt) | inibidores de fosfatidilinositol 3-quinase para tratamento de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |